GlaxoSmithKline’s two-drug HIV bet just paid off.
Despite a frantic effort to rush Ebola vaccines through testing during an epidemic, Merck will fall short in its goal to file its candidate this year.
As Emergent BioSolutions pushes toward its goal of reaching $1 billion in annual revenues, the company has secured an important regulatory milestone.
Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.
Pfizer faces a legal hurdle to its proposed Herceptin biosimilar now that Roche has sued for patent infringement.
A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
U.K. antitrust watchdogs are targeting Concordia and its pricing for liothyonine, a thyroid drug that now costs 57 times more than it did in 2006.
Pfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions.
Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.
Two of Roche's newest drugs—including the just-approved hemophilia therapy Hemlibra—racked up data that bolster their case for $1 billion-plus sales.